InfuSystem Releases Financial Results for Second Quarter 2026

ROCHESTER HILLS, Michigan—InfuSystem Holdings, Inc., a national healthcare service provider, facilitating outpatient care for durable medical equipment manufacturers and healthcare providers, reported its financial results for the 2026 second quarter (Q2).

“We delivered another strong quarter, achieving record revenue of $36.9 million and growing Adjusted EBITDA by 7.6%,” said Carrie Lachance, CEO of InfuSystem. “Our oncology business continued its steady momentum, surpassing $20 million in quarterly revenue for the first time, while wound care delivered exceptional growth driven by strong adoption of our new lymphedema compression therapy offerings. As our business continues to diversify, we remain focused on pursuing profitable growth while driving ever greater efficiencies.”

Q2 Overview

• Net revenues totaled $36.9 million, an increase of 2.6% versus the prior year.
• Patient services net revenue was $24.8 million, an increase of 15% versus the prior year.
• Device solutions net revenue was $12.1 million, a decrease of 16% versus the prior year.
• Gross profit was $21.4 million, an increase of 8% versus the prior year.
• Gross margin was 58%, an increase of 3% versus the prior year.
• Net income was $3.2 million, or $0.15 per diluted share, versus the prior year net income of $2.6 million, or $0.12 per diluted share.
• Adjusted earnings before interest, income taxes, depreciation and amortization (adjusted EBITDA) (non-GAAP) was $8.6 million, an increase of 8% versus the prior year.
• Adjusted EBITDA margin was 23.4%, an increase of 1.1% versus the prior year.
• Stock repurchases totaled $3.5 million for the quarter.
• Company liquidity totaled $55.2 million as of June 30, 2026.

Gross profit for the second quarter of 2026 of $21.4 million increased by $1.5 million, or 7.7%, compared to the second quarter of 2025. This increase was due to an increase in net revenues and a higher gross profit percentage of net revenue (gross margin). Gross margin was 58% during the second quarter of 2026 compared to 55.2% during the prior year period, an increase of 2.8%. Gross profit was higher in both the patient services and device solutions segments. Gross margin was higher in the device solutions segment and was lower in the patient services segment.

Selling and marketing expenses were $3 million for the second quarter of 2026, representing an increase of 10.5%, compared to the prior year. Selling and marketing expenses as a percentage of net revenues increased to 8.1% compared to 7.5% in the prior year period. This increase reflected an increase in sales team headcount, increased travel expenses and inflationary impacts, including an increase in employee healthcare expenses.